Europe Hematuria Treatment Market

Market Introduction

Hematuria is a medical condition where presence of blood is found in the urine. Generally, urine does not contain RBC and hence this can result in serious issue that may also cause kidney stones, urinary tract infection and other inherited diseases.

Moreover, the high prevalence hematuria associated indications is expected to bolster the market growth during the forecast period. However, undiagnosed cases of associated indications limit the growth of the Europe hematuria treatment market.

A variety of patients have reported progressive acute kidney injury (AKI) at admission and during hospitalization and mild proteinuria symptoms for hematuria, which are associated with adverse clinical outcomes in inpatients with COVID 19. Proteinuria and hematuria are reported to have an even higher prevalence in COVID-19 than AKI. Retrospective studies in China have reported that proteinuria and hematuria are associated with COVID-19 and with higher mortality. In addition, according to the European Kidney Association (ERACODA) COVID19 database established in March 2020, approximately 25% of kidney transplant patients are diagnosed with coronavirus. Therefore, an increase in COVID-positive patients is expected to be more likely to be treated for kidney disease.

Market Overview and Dynamics

The Europe hematuria treatment market is projected to reach US$ 313.8 million by 2028 from US$ 270.5 million in 2021; it is anticipated to grow at a CAGR of 2.1% from 2021 to 2028. The patients across the region mostly prefer at-home care services. Wearable and portable medical devices hold major potential to improve treatment by allowing patients to continue with their daily activities along with the dialysis process. For instance, at-home dialysis offers greater flexibility with work and lifestyle schedules for patients. In addition, the overall procedure of home hemodialysis is much simplified as compared to traditional dialysis. Thus, wearable and implantable devices could provide patients the freedom to work and perform their daily activities during treatment. Such advanced therapeutic alternatives are likely to drive the Europe hematuria treatment market in years to come.

Key Market Segments

In terms of type, the macroscopic hematuria segment accounted for the largest share of the Europe hematuria treatment market in 2020. In terms of treatment, the drugs segment accounted for the largest share of the Europe hematuria treatment market in 2020. In terms of indication, the urinary tract infection segment accounted for the largest share of the Europe hematuria treatment market in 2020. In terms of end user, the hospitals segment accounted for the largest share of the Europe hematuria treatment market in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the hematuria treatment market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, and Boehringer Ingelheim International GmbH.

Reasons to Buy Report

• To understand the Europe hematuria treatment market landscape and identify market segments that are likely to guarantee a strong return
• To comprehend the ever-changing market landscape and stay ahead in competition
• To efficiently plan merger and acquisition, and partnership deals in the Europe hematuria treatment market by identifying segments with the most promising probable sales
• To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
• To obtain market revenue forecast of the Europe hematuria treatment market based on various segments for the period 2021–2028

EUROPE HEMATURIA TREATMENT MARKET SEGMENTATION

By

Treatment

• Drugs
• Therapies
• Others 

By Indication

• Urinary Tract Infections
• Kidney Stones
• Urethritis
• Blood Cancer
• Bladder Stones
• Prostate Cancer
• Cystitis
• Trauma
• Vigorous Exercise
• Polycystic Kidney Disease
• Endometriosis
• Menstruation

By Type

• Macroscopic Hematuria
• Microscopic Hematuria
• Idiopathic Hematuria
• Jogger’s Hematuria

By End User

• Hospitals
• Clinics
• Ambulatory Surgical Centers (ASC's)
• Others

By Country

• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Companies Mentioned

• AstraZeneca
• Bristol-Myers Squibb Company
• F. HOFFMANN-LA ROCHE LTD.
• GlaxoSmithKline plc.
• Janssen Pharmaceuticals
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd
• Boehringer Ingelheim International GmbH

Europe Hematuria Treatment Strategic Insights

Strategic insights for the Europe Hematuria Treatment provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Hematuria Treatment Report Scope

Europe Hematuria Treatment Regional Insights

The geographic scope of the Europe Hematuria Treatment refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.